90Y-DOTA-hLL2: An agent for radioimmunotherapy of non-Hodgkin's lymphoma

Journal of Nuclear Medicine

Volumn 44, Issue 1, 2003, Pages 77-84

  Griffiths, Gary L ^a   Govindan, Serengulam V ^a   Sharkey, Robert M ^a   Fisher, Darrell R ^a   Goldenberg, David M ^a  

^a NONE

Author keywords

90Y; CD22; Dosimetry; DOTA; Humanized LL2

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CD22 ANTIGEN; CHELATING AGENT; EPRATUZUMAB; HLL2 MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY; PENTETIC ACID; UNCLASSIFIED DRUG; YTTRIUM 90; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; ANTINEOPLASTIC AGENT; HLL2 AGENT; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS; YTTRIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICAL BONE; DATA ANALYSIS; DOSIMETRY; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DECOMPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STABILITY; DRUG UPTAKE; FEMALE; GAMMA RADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; ROOM TEMPERATURE; STATISTICAL ANALYSIS; XENOGRAFT; ANIMAL; B CELL LYMPHOMA; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; METABOLISM; METHODOLOGY; REFERENCE VALUE; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG STABILITY; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; ISOTOPE LABELING; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; REFERENCE VALUES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; YTTRIUM RADIOISOTOPES;

EID: 0037207880     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001;39:195-201.
2. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001;39:181-194.
3. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
4. Stein R, Belisle E, Hansen HJ, Goldenberg DM. Epitope specificity of the anti-B cell lymphoma monoclonal antibody, LL2. Cancer Immunol Immunother. 1993; 37:293-298.
5. Leung SO, Goldenberg DM, Dion AS, et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol. 1995;32:1413-1427.
6. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 1995;55(suppl):5899s-5907s.
7. 111In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Cancer Res. 1999;5(suppl):3292s-3303s.
8. Leonard JP, Coleman M, Chadburn A, et al. Epratuzumab (hLL2, anti-CD22 humanized monoclonal antibody) is an active and well-tolerated therapy for refractory/relapsed diffuse large B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood. 2000;96(suppl 1):578a.
9. Leonard JP, Coleman M, Matthews JC, et al. Combination monoclonal antibody therapy for lymphoma: treatment with epratuzumab (anti-CD22) and rituximab (anti-CD20) is well tolerated [abstract]. Blood. 2001;98:844a.
10. Murthy S, Sharkey RM, Goldenberg DM, et al. Lymphoma imaging with a new technetium-99m labelled antibody, LL2. Eur J Nucl Med. 1992;19:394-401.
11. Mattes MJ, Shih LB, Govindan SV, et al. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody. Int J Cancer. 1997;71:429-435.
12. Stein R, Govindan SV, Chen S, Reed L, Spiegelman H, Griffiths GL. Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine. Crit Rev Oncol Hematol. 2001;39:173-180.
13. 131I. J Nucl Med. 2001;42:967-974.
14. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys. 1984;11: 638-645.
15. Watanabe N, Oriuchi N, Tanada S, et al. Effect of edetate calcium disodium on yttrium-90 activity in bone of mice. Ann Nucl Med. 1999;13:397-400.
16. Hnatowich DJ, Childs RL, Lanteigne D, Najafi A. The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method. J Immunol Methods. 1983;65:147-157.
17. Kozak RW, Raubitschek A, Mirzadeh S, et al. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res. 1989;49:2639-2644.
18. Sharkey RM, Motta-Hennessy C, Gansow OA, et al. Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice. Int J Cancer. 1990;46:79-85.
19. 111indium-OTA chelates: a simple and efficient method. Bioconjug Chem. 1994;5:101-104.
20. 90Y from cyclic and acyclic ligand-antibody complexes. Int J Rad Appl Instrum B. 1991;5:469-476.
21. 90Yttrium-labeled complementary-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies. Bioconjug Chem. 1998;9:773-782.
22. Losman MJ, Hansen HJ, Dworak H, et al. Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2). Cancer. 1997;80(suppl):2660-2666.
23. Losman MJ, Leung SO, Shih LB, et al. Development and evaluation of the specificity of a rat monoclonal anti-idiotype antibody, WN, to an anti-B-cell lymphoma monoclonal antibody, LL2. Cancer Res. 1995;55:5987s-5982s.
24. Cummins CH, Rutter EW, Fordyce WA. A convenient synthesis of bifunctional chelating agents based on diethylenetriaminepentaacetic acid and their coordination chemistry. Bioconjug Chem. 1991;2:180-186.
25. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamido reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem. 1984;142:68-78.
26. 90Y-labeled immunoconjugates. Cancer. 1994;73(suppl 3):951-957.
27. 90Y-labeled immunoconjugate. Cancer. 1994;73(suppl 3):958-965.
28. Camera L, Kinuya S, Garmestani K, et al. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1, 4, 7, 10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur J Nucl Med. 1994;21:640-646.
29. DeNardo GL, Kroger LA, DeNardo SJ, et al. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-1T-BAD conjugated monoclonal antibody (BrE-3). Cancer. 1994;73(suppl):1012-1022.
30. 111In radiolabels. J Nucl Med. 2001;42:1281-1287.
31. 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. J Nucl Med. 1999;40:268-276.
32. Y monoclonal antibody B3. Clin Cancer Res. 2000;6:1720-1730.
33. 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med. 2000;41:952-958.
34. 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res. 2000;6:3855-3863.
35. 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer. J Nucl Med. 2000; 41:337-344.
36. DeNardo GL, Kroger LA, Meares CF, et al. Comparison of DOTA-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 21T-BAD-ChL6 in breast cancer xenografts. Clin Cancer Res. 1998;4:2483-2490.
37. Kukis DL, Novak-Hofer 1, DeNardo SJ. Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer. Cancer Biother Radiopharm. 2001;16: 457-467.
38. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
39. DeNardo DG, Xiong CY, Shi XB, DeNardo GL, DeNardo SJ. Anti-HLA-DR/ anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm. 2001;16:525-535.
40. Karacay H, McBride WJ, Griffiths GL, et al. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide. Bioconjug Chem. 2000;11: 842-854.